Repatha: Ph III data

Top-line data from an open-label, international Phase III trial in 39 adult patients with LDL-C levels of 100-190 mg/dL despite regular apheresis every 1 or 2 weeks plus statin therapy (if tolerated) showed that subcutaneous Repatha every 2 weeks met the primary endpoint of reducing the need for LDL-C apheresis at weeks 5 and 6 vs. continuation of apheresis. Repatha also met the secondary endpoints of improving LDL-C, non-HDL-C and the ratio of total cholesterol to HDL-C at week 4 vs. continuation of apheresis. Patients received Repatha or continued apheresis for the first 6 weeks. At week 6, all patients received Repatha...